Biotech and medical business blog

Visit BioHealth Investor

Vanda Scores on Insomnia Phase III Trials (VNDA)

Posted on June 26, 2008

Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) is seeing shares rise this morning on news that its Phase III data showed Tasimelteon significantly improves sleep in patients with chronic insomnia. The positive top-line results from a Phase III trial showed that its investigational drug candidate, Tasimelteon, which it calls a novel melatonin agonist, met the primary endpoint [...]...

Original article link


phase